Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling

Fig. 7

Analysis of human DCs treated with sarcosine in presence of CXCR2 neutralizing antibody (a) Mean intracellular sarcosine measurements after sarcosine treatment ranged from 0.064 to 0.4 pg/cell (p<0.0001, ANOVA). Human PBMC-derived DCs were treated with sarcosine at 20mM and they were electroporated with CMV pp65-mRNA (antigen). Sarcosine levels were tested after DCs were taken out of sarcosine culture for 24 hours. b Flow cytometry of HLA-DR2, CD11c and CD86 in human DCs. c In vitro trans-well migration analysis of sarcosine treated-human mDCs demonstrating significant increase in migration of cells with sarcosine. DCs had increased migration with CCL19/21 alone (mean 19.58%) or sarcosine alone (mean 23.17%) compared to the control group (mean 7.833%). Sarcosine and chemokines resulted in increased migrated than either sarcosine or chemokines alone (mean 34.00%). Sarcosine migration effect was abrogated by adding anti-CXCR2 to both sarcosine (mean 9.667%) and sarcosine with CCL19/21 (mean 15.67%) (P <0.0001, one-way ANOVA, Human DCs were isolated and pooled from PBMC of five different healthy donor and experiment repeated three times). d Immunofluorescent microscopy picture observation of trans-well migration of sarcosine treated human DCs when CXCR2 neutralizing antibody added to the cultured medium. Migrated cells were stained with DAPI. Human DCs were isolated and pooled from PBMC of three different healthy donor and experiment repeated three times

Back to article page